Core Points - Alkermes plc is launching its 8th annual Alkermes Pathways Research Awards program, which will accept applications from September 15, 2025, to December 15, 2025, offering individual grants of up to $100,000 per project [1][2][3] - The program aims to support early-career researchers focusing on schizophrenia, bipolar I disorder, and newly included areas of sleep and circadian disturbances associated with these conditions [2][3] - Since its inception in 2018, the program has provided approximately $2.7 million in funding to 27 researchers across the United States [4] Company Overview - Alkermes plc is a mid-cap growth and value equity global biopharmaceutical company focused on developing innovative medicines in neuroscience [5] - The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline for neurological disorders [5]

Company Overview - Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company focused on developing innovative medicines for central nervous system (CNS) disorders, including schizophrenia, depression, and addiction. The company operates in a competitive landscape with peers like Biogen and Eli Lilly, positioning itself uniquely in the market with a diverse portfolio and strategic focus on CNS disorders [1] Market Performance - Over the past month, ALKS has gained approximately 6.97%, reflecting strong investor confidence and positive market sentiment. This gain is significant in a volatile market, indicating optimism about the company's future prospects. However, in the past 10 days, ALKS experienced a slight decline of 2.10%, which may present a buying opportunity for investors [2][5] Growth Potential - ALKS shows a promising growth potential of 51.46%, suggesting that the stock is currently undervalued. This potential for appreciation makes it an attractive option for growth-oriented investors. The company's strong fundamentals are indicated by its Piotroski Score of 9, signifying robust financial health and efficient management practices [3][5] Target Price and Technical Indicators - The target price for ALKS is set at $43, aligning with its growth potential and current market dynamics. Achieving this target would represent a significant upside from its current trading levels, enhancing its appeal for investors. Additionally, ALKS has recently touched a local minimum, indicating that the stock may have bottomed out, which, combined with its strong fundamentals, enhances its attractiveness as a potential investment [4]

Core Points - Alkermes plc held a conference call to discuss the results of the Vibrance-1 Phase II study of alixorexton in patients with narcolepsy type 1 [2] Group 1 - The conference call featured key executives including the CEO Richard Pops and Chief Medical Officer Dr. Craig Hopkinson, along with the lead investigator Professor Giuseppe Plazzi [2] - A press release and slide presentation related to the study results were made available on the Investors section of alkermes.com [2]

Company Overview - CoinShares, a cryptocurrency asset manager listed in Sweden, is preparing to go public in the U.S. through a SPAC agreement, which will value the company at $1.2 billion and lead to its delisting from the Swedish market [2] - The company currently manages approximately $10 billion in assets, a figure that has tripled over the last two years, and has expanded its product offerings from four in 2021 to a suite of 32 products across four platforms [4] Market Position - CoinShares is recognized as the fourth-largest manager of digital asset ETP products globally, following BlackRock, Grayscale, and Fidelity, and holds the top position in Europe, the Middle East, and Africa with a 34% market share [3] Industry Context - The U.S. is becoming a central hub for digital assets, with CoinShares aiming to capitalize on the growing investor demand and favorable regulatory environment for cryptocurrencies [3] - The trend of crypto firms going public in the U.S. is gaining momentum, with other companies like Circle and Bullish successfully listing, indicating a shift in traditional finance's openness to digital assets [5][6]

Core Insights - Alkermes plc announced positive results from the Vibrance-1 phase 2 study of alixorexton, a novel orexin 2 receptor agonist for narcolepsy type 1, demonstrating significant improvements in wakefulness, cognition, and fatigue with once-daily dosing [1][2][4] Study Results - The Vibrance-1 study involved 92 patients and showed statistically significant improvements in mean sleep latency on the Maintenance of Wakefulness Test (MWT) at week six, with mean sleep latencies of approximately 24, 26, and 28 minutes for the 4 mg, 6 mg, and 8 mg doses respectively, compared to a baseline of about 3 minutes [4][5] - Alixorexton also achieved significant improvements in the Epworth Sleepiness Scale (ESS) scores, with baseline scores of 18.5 and reductions to the normal range (a score of 10) across all doses [4][5] - More than 40% of patients on the 6 mg and 8 mg doses experienced a 100% reduction in cataplexy during week six [4][5] Safety Profile - Alixorexton was generally well tolerated across all tested doses, with no serious treatment-emergent adverse events reported [6][4] - The most common mild to moderate adverse events included pollakiuria, insomnia, and blurred vision, with most events resolving within the first week of treatment [6][4] Future Plans - Alkermes plans to initiate a global phase 3 program for alixorexton in the first quarter of 2026, following the positive phase 2 results [8][4] - The company is also advancing other orexin-targeted therapeutics into first-in-human studies this year [8]

Core Viewpoint - Alkermes reported a strong second quarter for 2025, with earnings and proprietary product sales exceeding expectations, despite a slight decline in total revenues compared to the previous year [2][3][5]. Financial Performance - Alkermes reported earnings from continuing operations of 52 cents per share, beating the Zacks Consensus Estimate of 41 cents and slightly lower than 53 cents per share from the year-ago quarter [2]. - Total revenues for the second quarter were $390.7 million, a decrease of 2.1% year over year, but significantly above the Zacks Consensus Estimate of $339 million [3]. - Sales from proprietary products grew 14% year over year to $307.2 million, surpassing management's expectations of $260-$280 million [5]. Product Sales Breakdown - Vivitrol sales increased 9% year over year to $121.7 million, exceeding the Zacks Consensus Estimate of $111 million [6]. - Aristada sales rose 18% year over year to $101.3 million, beating the Zacks Consensus Estimate of $84 million [6]. - Lybalvi generated sales of $84.3 million, up 18% year over year, also surpassing the Zacks Consensus Estimate of $79 million [7]. Revenue Sources - Alkermes' revenue sources include net sales from proprietary products and manufacturing/royalty revenues from partnered products [4]. - Manufacturing and royalty revenues decreased 35.8% year over year to $83.4 million, with specific contributions from Biogen's Vumerity and other products [7][8]. Expenses and Cash Position - Research and development expenses increased by almost 30% year over year to $77.4 million, driven by ongoing studies on pipeline candidate alixorexton [8]. - As of June 30, 2025, Alkermes had cash and cash equivalents of $1.05 billion, up from $916.2 million as of March 31, 2025 [9]. Guidance and Estimates - Alkermes reiterated its financial guidance for 2025, expecting total revenues of $1.34-$1.43 billion [10]. - The company anticipates net sales of Vivitrol to be $440-$460 million, Aristada sales to be $335-$355 million, and Lybalvi's net sales to be in the range of $320-$340 million [11]. Market Position and Trends - Estimates for Alkermes have trended downward recently, with a consensus estimate shift of -14.21% [12]. - Alkermes holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [14].

Core Insights - Alkermes plc is set to present detailed results from its Vibrance-1 phase 2 study on alixorexton for narcolepsy type 1 at the World Sleep Congress in Singapore from September 5-10, 2025, and during an investor webcast on September 8, 2025 [1][2][7] Company Overview - Alkermes plc is a mid-cap global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing various neurological disorders including narcolepsy and idiopathic hypersomnia [10] Study Details - The Vibrance-1 study is a phase 2, randomized, double-blind, placebo-controlled trial involving 92 participants, evaluating the safety and efficacy of alixorexton in adults with narcolepsy type 1 [8] - Participants were assigned to receive one of three doses of alixorexton (4 mg, 6 mg, or 8 mg) or placebo once daily for six weeks, with primary and secondary endpoints focusing on wakefulness and other narcolepsy symptoms [8] Presentation Highlights - Three oral presentations will cover the safety and efficacy of alixorexton, improvements in fatigue and cognitive function, and the study design for the Vibrance-3 study evaluating alixorexton in idiopathic hypersomnia [4][5][6] - The presentations will take place during the "Targeting the orexin pathway: Emerging pharmacotherapies for narcolepsy type 1" session on September 8, 2025 [4] Research Community Engagement - The World Sleep Congress will feature leading researchers and clinicians discussing new datasets on orexin 2 receptor agonists, highlighting the ongoing commitment to improving care for patients with hypersomnolence disorders [2][3]

Group 1 - The article highlights Alkermes plc (NASDAQ: ALKS) as a focus for investment discussions, particularly in the context of covered call opportunities in the biotech sector [1] - Alkermes recently reported its quarterly results, marking the first analysis of the company since the previous article published nearly a year ago [1] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions and weekly updates on market commentary and portfolio performance [1] Group 2 - The article does not provide any specific financial metrics or performance data for Alkermes plc [3]

Core Insights - Alkermes plc reported earnings from continuing operations of 52 cents per share for Q2 2025, surpassing the Zacks Consensus Estimate of 41 cents and slightly down from 53 cents in the same quarter last year [1] - Total revenues for the second quarter were $390.7 million, a decrease of 2.1% year-over-year, primarily due to lower manufacturing and royalty revenues, but still exceeding the Zacks Consensus Estimate of $339 million [1][6] Financial Performance - Proprietary product sales increased by 14% year-over-year to $307.2 million, driven by strong demand for Vivitrol, Aristada, and Lybalvi, exceeding management's expectations of $260-$280 million [4][6] - Manufacturing and royalty revenues fell by 35.8% year-over-year to $83.4 million, negatively impacting overall revenue performance [6][8] - Research and development expenses rose by nearly 30% year-over-year to $77.4 million, attributed to higher costs related to ongoing studies for the investigational pipeline candidate, alixorexton [9] Product Sales Breakdown - Vivitrol sales grew by 9% year-over-year to $121.7 million, surpassing the Zacks Consensus Estimate of $111 million [7] - Aristada sales increased by 18% year-over-year to $101.3 million, exceeding the Zacks Consensus Estimate of $84 million [7] - Lybalvi generated sales of $84.3 million, up 18% year-over-year, also beating the Zacks Consensus Estimate of $79 million [8] Guidance and Future Outlook - Alkermes reiterated its 2025 financial guidance, expecting total revenues between $1.34 billion and $1.43 billion, with specific net sales targets for Vivitrol, Aristada, and Lybalvi [11] - The company is planning to initiate a global phase III program for alixorexton in patients with narcolepsy type 1 following positive results from the phase II Vibrance-1 study [12][14] Pipeline Development - The phase II Vibrance-1 study showed statistically significant improvements in wakefulness for patients treated with alixorexton compared to placebo [13] - Alixorexton is also being studied for narcolepsy type 2 and idiopathic hypersomnia, with data from the Vibrance-2 study expected in the fall [15][16]

Core Insights - Alkermes reported revenue of $390.66 million for the quarter ended June 2025, reflecting a year-over-year decline of 2.1% and an EPS of $0.52 compared to $0.72 a year ago, exceeding the Zacks Consensus Estimate of $338.57 million by 15.38% and delivering an EPS surprise of 26.83% [1] Revenue Breakdown - Manufacturing and Royalty revenues were $83.42 million, surpassing the average estimate of $61.5 million, but showing a year-over-year decline of 35.8% [4] - Product sales, net, reached $307.24 million, exceeding the estimated $276.98 million and representing a year-over-year increase of 14.1% [4] - Proprietary Sales for VIVITROL amounted to $121.7 million, above the estimated $111.47 million, marking an 8.8% increase year-over-year [4] - Proprietary Sales for ARISTADA were $101.3 million, exceeding the average estimate of $84.2 million, with a year-over-year growth of 17.8% [4] - Proprietary Sales for LYBALVI reached $84.3 million, compared to the estimated $79.41 million, reflecting an 18.1% year-over-year increase [4] - Manufacturing and Royalty Revenues for VUMERITY were $39.4 million, surpassing the estimated $27.92 million, with an 11.9% year-over-year increase [4] Stock Performance - Alkermes shares have returned -8.6% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change, and the stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]